Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Noemi Puig

Showing results (31-40 of 81) with videos related to

Pageof 9
Sort By:
Blood|July 30, 2021
Validation of the International Myeloma Working Group standard response criteria in the PETHEMA/GEM2012MENOS65 study: are these times of change?Ana Jiménez-Ubieto, Bruno Paiva, Noemi Puig, et al.
Advances in Therapy|May 12, 2025
Comparative Efficacy of Ciltacabtagene Autoleucel Versus Standard-of-Care Treatments for Patients with Previously Treated Relapsed or Refractory Multiple Myeloma: A Matching-Adjusted Indirect ComparisonNoemi Puig, Joris Diels, Suzy van Sanden, et al.
British Journal of Haematology|August 20, 2013
Evaluating gene expression profiling by quantitative polymerase chain reaction to develop a clinically feasible test for outcome prediction in multiple myelomaMaría E Sarasquete, Joaquín Martínez-López, María C Chillón, et al.
Annals of Hematology|May 10, 2021
Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the USFaith Davies, Robert Rifkin, Caitlin Costello, et al.
Blood|April 24, 2019
Role of urine immunofixation in the complete response assessment of MM patients other than light-chain-only diseaseJuan-José Lahuerta, Ana Jiménez-Ubieto, Bruno Paiva, et al.
Blood|December 16, 2015
Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under LenDex: a longitudinal analysisBruno Paiva, María Victoria Mateos, Luis Ignacio Sanchez-Abarca, et al.
Blood|December 4, 2023
Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myelomaCamila Guerrero, Noemi Puig, María-Teresa Cedena, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 27, 2020
Summary of the 2019 Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune ProfilingSarah A Holstein, Alan Howard, David Avigan, et al.
Blood Cancer Journal|October 31, 2020
Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myelomaAlejandro Medina, Noemi Puig, Juan Flores-Montero, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 31, 2022
More Than 2% of Circulating Tumor Plasma Cells Defines Plasma Cell Leukemia-Like Multiple MyelomaTomas Jelinek, Renata Bezdekova, David Zihala, et al.
Pageof 9

Showing results (31-40 of 81) with videos related to

Sort By:
Pageof 9
Blood|July 30, 2021
Validation of the International Myeloma Working Group standard response criteria in the PETHEMA/GEM2012MENOS65 study: are these times of change?Ana Jiménez-Ubieto, Bruno Paiva, Noemi Puig, et al.
Advances in Therapy|May 12, 2025
Comparative Efficacy of Ciltacabtagene Autoleucel Versus Standard-of-Care Treatments for Patients with Previously Treated Relapsed or Refractory Multiple Myeloma: A Matching-Adjusted Indirect ComparisonNoemi Puig, Joris Diels, Suzy van Sanden, et al.
British Journal of Haematology|August 20, 2013
Evaluating gene expression profiling by quantitative polymerase chain reaction to develop a clinically feasible test for outcome prediction in multiple myelomaMaría E Sarasquete, Joaquín Martínez-López, María C Chillón, et al.
Annals of Hematology|May 10, 2021
Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the USFaith Davies, Robert Rifkin, Caitlin Costello, et al.
Blood|April 24, 2019
Role of urine immunofixation in the complete response assessment of MM patients other than light-chain-only diseaseJuan-José Lahuerta, Ana Jiménez-Ubieto, Bruno Paiva, et al.
Blood|December 16, 2015
Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under LenDex: a longitudinal analysisBruno Paiva, María Victoria Mateos, Luis Ignacio Sanchez-Abarca, et al.
Blood|December 4, 2023
Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myelomaCamila Guerrero, Noemi Puig, María-Teresa Cedena, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 27, 2020
Summary of the 2019 Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune ProfilingSarah A Holstein, Alan Howard, David Avigan, et al.
Blood Cancer Journal|October 31, 2020
Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myelomaAlejandro Medina, Noemi Puig, Juan Flores-Montero, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 31, 2022
More Than 2% of Circulating Tumor Plasma Cells Defines Plasma Cell Leukemia-Like Multiple MyelomaTomas Jelinek, Renata Bezdekova, David Zihala, et al.
Pageof 9